Literature DB >> 1564123

Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects.

M D Freedman1.   

Abstract

Discovered early in this century consequent to investigations of a bovine hemorrhagic disease, the oral anticoagulants inhibit a post translational modification required for various hepatically derived serine proteases to become active. These include Factors II, V, VII and X. Through their effect on Proteins S and C, the extrinsic pathway is also effected. While most of these agents exist as optically active enantiomers, with differing kinetics and pharmacologic profiles, they are generally administered in the clinic as racemic mixtures. Over the last 45 years, various studies have sought to better evaluate the role of the oral anticoagulation in both prevention and treatment of various types of thrombo-occlusive and -embolic disease. Such exercises have allowed us to better understand the pathophysiology of those diseases as well as to better characterize the pre-thrombotic state.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1564123     DOI: 10.1002/j.1552-4604.1992.tb03827.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  15 in total

Review 1.  Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.

Authors:  Michael Ganetsky; Kavita M Babu; Steven D Salhanick; Robert S Brown; Edward W Boyer
Journal:  J Med Toxicol       Date:  2011-12

Review 2.  Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective.

Authors:  Shivanshu Madan; Shenil Shah; Sasan Partovi; Sahil A Parikh
Journal:  Cardiovasc Diagn Ther       Date:  2014-08

Review 3.  Stroke prevention treatment of patients with atrial fibrillation: old and new.

Authors:  Simerpreet Bal; Pawan Ojha; Michael D Hill
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 4.  Use of novel oral anticoagulant agents in venous thromboembolism.

Authors:  Shivanshu Madan; Shenil Shah; Patrick Dale; Sasan Partovi; Sahil A Parikh
Journal:  Cardiovasc Diagn Ther       Date:  2016-12

5.  Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.

Authors:  Saurabh Singh Rathore; Surendra Kumar Agarwal; Shantanu Pande; Sushil Kumar Singh; Tulika Mittal; Balraj Mittal
Journal:  Indian J Clin Biochem       Date:  2011-05-01

Review 6.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

7.  Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery.

Authors:  Pouya N Dayani; M Gilbert Grand
Journal:  Trans Am Ophthalmol Soc       Date:  2006

8.  Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study.

Authors:  Shadi Yaghi; Eva Mistry; Ava L Liberman; James Giles; Syed Daniyal Asad; Angela Liu; Muhammad Nagy; Ashutosh Kaushal; Idrees Azher; Brian Mac Grory; Hiba Fakhri; Kiersten Brown Espaillat; Hemanth Pasupuleti; Heather Martin; Jose Tan; Manivannan Veerasamy; Charles Esenwa; Natalie Cheng; Khadean Moncrieffe; Iman Moeini-Naghani; Mithilesh Siddu; Erica Scher; Tushar Trivedi; Aaron Lord; Karen Furie; Salah Keyrouz; Amre Nouh; Christopher R Leon Guerrero; Adam de Havenon; Muhib Khan; Nils Henninger
Journal:  Stroke       Date:  2020-08-06       Impact factor: 7.914

Review 9.  Prevention and treatment of venous thromboembolism.

Authors:  G F Pineo; R D Hull
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

10.  Factors associated with pseudoaneurysm development and necessity for reintervention: a single centre study.

Authors:  Jonathan Delf; Sanjeev Ramachandran; Syed Mustafa; Abdullah Saeed; Neghal Kandiyil
Journal:  Br J Radiol       Date:  2019-05-15       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.